Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21028301 | 0.81 | PTGDR2 (0.42) | PTGDR2TBXA2RPTGDRSLC6A3 | |
| SCHEMBL21027848 | 0.81 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRSLC6A3 | |
| SCHEMBL21027849 | 0.81 | PTGDR2 (0.42) | PTGDR2TBXA2RPTGDRSLC6A3CYP2C9 | |
| SCHEMBL21027880 | 0.80 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRSLC6A3 | |
| SCHEMBL21028029 | 0.78 | PTGDR2 (0.40) | PTGDR2TBXA2RPTGDRSLC6A3 | |
| SCHEMBL21027850 | 0.75 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRSLC6A3CYP2C9 | |
| SCHEMBL21027882 | 0.75 | PTGDR2 (0.45) | PTGDR2TBXA2RPTGDRSLC6A3 | |
| SCHEMBL21027881 | 0.74 | PTGDR2 (0.39) | PTGDR2TBXA2RPTGDRSLC6A3CYP2C9 | |
| SCHEMBL21027846 | 0.72 | PTGDR2 (0.55) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL21027847 | 0.71 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRSLC6A3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |